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Ex vivo toxicological evaluation of experimental anticancer 
gold(I) complexes with lansoprazole-type ligands 
N. Estrada-Ortiz,a E. Lopez-Gonzales,a Ben Woods,b Stefan Stürup,c I. A. M. de Graaf,a G. M. M. 
Groothuis, a* A. Casinia,b,d* 
Gold-based compounds are of great interest in the field of medicinal chemistry as novel therapeutic (anticancer) agents due 
to their peculiar reactivity and mechanisms of action with respect to organic drugs. Despite their promising pharmacological 
properties, the possible toxic effects of gold compounds need to be carefully evaluated in order to optimize their design and 
applicability. This study reports on the potential toxicity of three experimental gold-based anticancer compounds featuring 
lansoprazole ligands (1-3) studied in an ex-vivo model, using rat precision cut kidney and liver slices (PCKS and PCLS, 
respectively). The results showed a different toxicity profile for the tested compounds, with the neutral complex 2 being the 
least toxic, even less toxic than cisplatin, followed by the cationic complex 1. The dinuclear cationic gold complex 3 was the 
most toxic in both liver and kidney slices. This result correlated with the metal uptake of the different compounds assessed by 
ICP-MS, where complex 3  showed the highest acummulation of gold in liver and kidney slices. Interestingly compound 1 
showed the highest selectivity towards cancer cells compared to the healthy tissues. Histomorphology evaluation showed a 
similar pattern for all three Au(I) complexes, where the distal tubular cells suffered the most extensive damage, in contrast to 
the damage in the proximal tubulus induced by cisplatin. The binding of representative gold compunds with the model 
ubiquitin was also studied by ESI-MS, showing that after 24 h incubation only ‘naked’ Au ions are bound to the protein 
following ligands’ loss. The mRNA expression of stress response genes appeared to be similar for both evaluated organs, 
suggesting oxidative stress as the possible mechanism of toxicity. The obtained results open new perspectives towards the 
design and testing of bifunctional gold complexes with chemotherapeutic applications. 
 
Introduction 
In the drug development process, it is crucial to anticipate 
possible side effects and predict toxicity before starting clinical 
trials of potential drug-like compounds not only in animal 
experiments but also in human-derived in vitro models. 2-D 
single-cell models are by far the most commonly used models to 
predict efficacy and toxicity in humans. The advantage of these 
models is the variety of cell types available to study, including 
primary cells, cell lines, stem cells and cancer cells. The main 
disadvantage is the absence of the complexity of a tissue, with its 
multitude of cell types playing different roles and secreting 
different signaling molecules, and the absence of a proper extra 
cellular matrix to maintain and regulate the function and 
activities of the specific tissue 1. Therefore, animal models are 
widely used, where the complexity of a whole organism is intact. 
However, the use of animals for preclinical studies exposes two 
important problems: the large number and high discomfort of 
animals used bring about ethical objections and the translation of 
such studies from any species (even primates) to the humans is 
not always accurate and presents a risk to patients in the first 
phases of clinical trials 2–5.  
In the past decades, the technique known as precision cut tissue 
slices (PCTS) became a powerful technology, which can be 
applied to many organs 6–10. PCTS contain all cell types of the 
tissue in their natural environment, with intercellular and cell-
matrix interactions remaining intact, making the technique an 
ideal ex vivo model for human diseases, such as fibrosis and 
cirrhosis.11–14 Additionally, the PCTS technique offers the 
opportunity to test the activity, metabolism, transport and 
toxicity of new drug candidates, including comparison between 
species and organs6–11,14–17. PCTS is an FDA-approved model for 
drug toxicity and metabolism studies and offers an opportunity 
of reducing the number of animals used in pre-clinical studies 
6,7,10. Using PCTS it is possible to obtain valuable knowledge on 
the structure-toxicity relationship of experimental compounds, 
enabling further optimization and selection of better candidates 
with improved properties and reduced toxicity in healthy tissue. 
Recently, we have successfully used PCTS to study the toxic 
effects of experimental anticancer organometallic compounds 18–
22, aminoferrocene-containing pro-drugs23, ruthenium-based 
kinase inhibitors24, as well as supramolecular metallacages as 
drug delivery systems 15,25.  
Here, we applied the PCTS technology to study the toxicity of 
three bifunctional metallodrugs, containing gold(I) ions 
complexed with a lansoprazole moiety (Figure 1), in healthy rat 
liver and kidney slices, which are the most sensitive to drug-
induced injury. In a previous study, the three compounds were 
studied for their anticancer effects in human cancer cells in vitro, 
showing promising activity profiles against cisplatin resistant 
human A2780 ovarian cancer cells26.  
Following the clinical success of the Pt(II) complex cisplatin 
(Figure 1) a large number of metal-containing compounds were 
developed with interesting cytotoxic activities and 
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pharmacological profiles27–33. Among them, gold-based 
complexes occupy a relevant family, due to their different 
possible oxidation states (e.g. Au(I) and Au(III)), stability and 
ligand exchange reactions, conferring them different 
mechanisms of action compared to cisplatin 32,34,35. As an 
example, the Au(I) complex auranofin (Figure 1) is in clinical 
trials at present for the treatment of different cancers 34,36. 
Lansoprazole is a drug currently in use for the treatment of ulcers 
and gastroesophageal reflux disease.37,38 The postulated 
mechanism of action is to selectively inhibit the membrane 
enzyme H+/K+ ATPase in gastric parietal cells 37,39. This H+/K+ 
ATPase is a proton pump located among others in the apical 
membrane of parietal cells and is responsible for gastric acid 
secretion. Proton pump inhibitors (PPIs) exert their effects by 
blocking the translocation of H+ into the stomach content thereby 
preventing acid formation and increasing the pH in the stomach 
37,40.  
Proton pumps are also found in other cell types, such as cancer 
cells 41. Thus, it has been proposed that PPIs, such as 
lansoprazole, can modify the acidic microenvironment present in 
most solid tumours and help to sensitize them to cytotoxic 
anticancer drugs 39,42–44.  
Within this context, in the last decade, several studies have 
shown a potential application in cancer research for the use of 
proton pump inhibitors to revert chemoresistance and increase 
chemosensitivity of different human tumour cells for several 
cytotoxic drugs 26,45.  
In the present study, we have evaluated the experimental 
anticancer Au(I) complexes featuring lansoprazole ligands for 
their toxicity in the PCTS model. These studies are necessary to 
assess the compounds’ potential as drug candidates for further 
preclinical investigation. Specifically, determination of the ATP 
content and histomorphological studies were conducted on 
PCTS from rat liver and kidney treated with the Au(I) complexes 
in comparison to lansoprazole, cisplatin and auranofin. In 
addition, the relationship between toxicity and metal 
accumulation in the tissue slices was determined using 
inductively coupled plasma mass spectrometry (ICP-MS). 
Moreover, the reactivity of two of the gold compounds with the 
model protein ubiquitin was studied by ESI-MS in aqueous 
environment. Finally, to get more insight into the possible 
mechanism of toxicological action, the mRNA expression of 
specific stress markers in liver and kidney slices was assessed, 
including expression of genes coding for proteins that play 
important roles in the pathways of oxidative stress, apoptosis and 
hypoxia.   
 
Experimental  
 
Synthesis of the Au(I) complexes 
The gold compounds 1-3 were prepared according to previously 
published procedures26 and their identity and purity (≥95%) were 
unambiguously established using high-resolution mass 
spectrometry, NMR spectroscopy and elemental analysis (see 
supplementary material for details).  Auranofin was purchased 
from Alfa-Aesar and cisplatin from Sigma-Aldrich. 
 
 
Figure 1. Compounds evaluated in this study. 
 
Preparation of rat Precision-Cut Liver and Kidney Slices 
(PCLS, PCKS)  
Male Wistar rats (Charles River, France) of 250-300 g were 
housed under a 12 h dark/light cycle at constant humidity and 
temperature. Animals were permitted ad libitum access to tap 
water and standard lab chow. All experiments were approved by 
the committee for care and use of laboratory animals of the 
University of Groningen and the study complies with the 
ARRIVE guidelines and was carried out in accordance with the 
EU directive 2010/63/EU for animal experiments. 
Kidneys and livers were harvested from the same rats 
(anesthetized with isoflurane) and immediately placed in 
University of Wisconsin solution (UW, ViaSpan, 4⁰ C) until 
further use. After removing fat, kidneys were cut in half 
lengthwise using a scalpel, and cortex cores of 5 mm diameter 
were made from each half perpendicular to the cut surface using 
disposable Biopsy Punches (KAI medical, Japan). Whereas, the 
liver cores were prepared by using a hollow drill bit. PCKS and 
PCLS were made as described by de Graaf et al. 6,7. The cores 
were sliced with a Krumdieck tissue slicer (Alabama R&D, 
Munford, AL, USA) in ice-cold Krebs-Henseleit buffer, pH 7.4 
saturated with carbogen (95% O2 and 5% CO2).  
Liver slices (ca. 5 mg, ~250 μm thickness) and kidney slices (ca. 
3 mg, ~150 μm thickness), were incubated individually in 12-
well plates (Greiner bio-one GmbH, Frickenhausen, Austria), at 
37°C in 1.3 mL Williams’ medium E (WME, Gibco by Life 
Technologies, UK) with glutamax-1, supplemented with 25 mM 
D-glucose (Gibco) and streptomycin (Gibco) (PCLS) 
ciprofloxacin HCl (PCKS) (10 µg/mL, Sigma-Aldrich, 
Steinheim, Germany) in an incubator (Panasonic biomedical) in 
an atmosphere of 80% O2 and 5% CO2 with shaking (90 
times/min). Slices were pre-incubated 1 h and then transferred to 
plates with fresh medium with the tested compounds to remove 
debris and dead cells. Stock solutions of complexes 1 to 3, 
auranofin and cisplatin were prepared by diluting a stock solution 
(10-2 M in DMSO or ethanol in the case of auranofin; 10-3 M in 
water for cisplatin). The final concentration of DMSO and 
ethanol during the PCLS and PCKS incubation was always 
below 1 and 0.025 %, respectively to exclude solvent toxicity. 
For each treatment, three slices were incubated individually for 
24 h.  
 
 
Viability and TC50 determination 
 
 
After the incubation, slices were collected for ATP and protein 
determination, by snap freezing them in 1 ml of ethanol (70% 
v/v) containing 2 mM EDTA with pH=10.9. After thawing the 
slices were homogenized using a mini bead beater and 
centrifuged. The supernatant was used for the ATP essay and the 
pellet was dissolved in 5N NaOH for the protein essay. The 
viability of PCKS was determined by measuring the ATP using 
the ATP Bioluminescence Assay kit CLS II (Roche, Mannheim, 
Germany) as described previously7. The ATP content was 
corrected by the protein amount of each slice and expressed as 
pmol/μg protein. The protein content of the PCKS was 
determined by the Bio-Rad DC Protein Assay (Bio-Rad, Munich, 
Germany) using bovine serum albumin (BSA, Sigma-Aldrich, 
Steinheim, Germany) for the calibration curve. The TC50 value 
was calculated as the concentration reducing the viability of the 
slices by 50%, in terms of ATP content corrected by the protein 
amount of each slice and relative to the slices without any 
treatment using a nonlinear fitting of log(concentration 
compound) vs response and is presented as a mean (± SD) of at 
least three independent experiments. 
 
ICP-MS 
After incubation for 24h with concentrations of 5 and 10 µM of 
complexes 1, 2 and cisplatin, 1 and 5 µM of complex 3, PCKS 
and PCLS were snap-frozen and stored at -80°C until the 
analysis. 
 
Sample preparation  
The tissue samples (triplicate slices combined) were digested 
with 100 µL concentrated nitric acid overnight, resulting in 
complete dissolution of all samples. 100 µL concentrated 
hydrochloric acid and 800 µL milliQ were added to produce a 
volume of 1,00 mL. Prior to analysis the samples were diluted 
20 times with 0.56% HNO3/0.1% HCl. 
 
ICP-MS analysis 
The Au and Pt contents were quantified applying a Perkin Elmer 
(Waltham, MA, USA) Sciex Elan 6100 DRC-e ICP-MS 
instrument, equipped with a Cetac ASX-110FR autosampler, a 
0.2 mL min-1 MicroMist U-series pneumatic concentric 
nebulizer (Glass Expansion, West Melbourne Vic, Australia) and 
a PC3 cyclonic spray chamber (Elemental Scientific Inc., 
Omaha, NE, USA). ICP-MS RF power, lens voltage and 
nebulizer gas and flow were optimized on a daily basis and other 
settings were: 1 sweep/reading, 25 readings/replicate, 5 
replicates, 50 ms dwell time. 197Au+, 195Pt+, and 194Pt+ isotopes 
were monitored. Pt and Au concentrations were determined by 
external calibration (0-20 ppb Pt and Au). LODs were 0.1 and 
0.2 µg L-1 for Pt and Au, (3*SD on blank, n=10) and the spike 
recovery were 102% and 99% for Pt and Au, respectively. Pt and 
Au single element PlasmaCAL standards (SCP Science, Quebec, 
Canada) were used and the standards were prepared in a mixture 
of 0.1% HCl and 0.65% subboiled HNO3 in MilliQ water. This 
mixture was furthermore used to dilute samples after digestion 
and as blank solution. 
Histomorphology 
After 24 h incubation with 25 µM for complexes 1, 2 and 
cisplatin, 10 µM for complex 3 and 5 µM for auranofin, kidney 
slices were fixated in 4% formalin for 24 hours and stored in 70% 
ethanol at 4⁰ C until processing for morphology studies. After 
dehydration, the slices were embedded in paraffin and 4 μm 
sections were made, which were mounted on glass slides and 
H&E and PAS staining were used for histopathological 
evaluation. First, the sections were deparaffinised with xylene 
and ethanol 100%. For the H&E staining the glass slides were 
hydrated in 50% ethanol, followed by hematoxylin staining for 5 
minutes, then rinsed with tap water and washed with 50% acidic 
ethanol (1 % HCl aqueous solution) and 80% alkaline ethanol 
(0.02 % NH3 aqueous solution), and subsequently the sections 
were stained with eosin for 2 minutes and washed with ethanol 
100% and xylene. For the PAS staining the sections were washed 
with distilled water, followed by treatment with a 1% aqueous 
solution of periodic acid for 20 minutes and Schiff reagent for 20 
minutes, the slides were rinsed with tap water, and finally a 
counterstain with hematoxylin for 5 minutes was used to 
visualize the nuclei. 
 
Determination of stress markers mRNA expression 
RNA isolation  
Three precision cut kidney and liver slices from each treatment 
group were snap-frozen in RNase free Eppendorf’s. RNA was 
isolated with the Maxwell® 16 simplyRNA Tissue Kit 
(Promega, Leiden, the Netherlands). Slices were homogenised in 
homogenisation buffer using a minibead beater. The homogenate 
was diluted 1:1 with lysis buffer. The mixture was processed 
according to the manufacturer’s protocol using the Maxwell 
machine. RNA concentration was quantified on a NanoDrop One 
UV-Vis Spectrophotometer (Thermoscientific, Wilmington, US) 
right before conversion to cDNA.  
 
cDNA generation 
RNA samples were diluted to 0.5 μg in 8.5 μL of RNAse free 
water. cDNA was generated from RNA using random primers 
with TaqMan Reverse Transcription Reagents Kits (Applied 
Biosystems, Foster City, CA). To each sample the following 
solutions were added: 2.5 μL 5x RT-buffer, 0.25 μL 10mM 
dNTP’s, 0.25 μL Rnasin (10 units), 0.5 μL M-MLV Reverse 
Transcriptase (100 units), 0.5 μL random primers. cDNA was 
generated in the Eppendorf mastercycler (Hamburg, Germany) 
with a gradient of 20°C for 10 min, 42°C for 30 min, 20°C for 
12 min, 99°C for 5 min and finally, 20°C for 5 min. 
 
qRT-PCR 
Real-time quantitative RT-PCR was used to determine relative 
mRNA levels of a set of specific genes involved in toxicity 
pathways. RT-PCR was performed using SensiMixTM SYBR 
Low-ROX kit (Bioline, London, UK) with the QuantStudio 7 
Flex Real-Time PCR System (Thermoscientific, Wilmington, 
US) with 1 cycle of 10 min at 95°C, 40 cycles of 15 sec at 95°C 
and 25 sec at 60°C, with a final dissociation stage of 15 sec at 
95°C, 1 min at 60°C and 15 sec at 95°C. cDNA for each sample 
was diluted to 2 ng/μL and measured in triplicate. All primers 
  
 
(Table 1) were purchased from Sigma-Aldrich. Fold induction of 
each gene was calculated using the housekeeping gene GAPDH. 
Table 1. Primer sequences used in qPCR. 
 
Statistics 
Three independent experiments (with exception of ICP-MS 
which was performed twice) were performed using slices in  
triplicates from each rat kidney or liver. The TC50 values were 
calculated as the concentration reducing the viability of the slices 
by 50%, relative to the untreated samples using a nonlinear 
fitting of log(concentration compound) vs response 
and is presented as a mean (± SD) of at least three independent 
experiments. Statistical testing was performed with one-way 
ANOVA with each individual experiment as random effect with 
a Tukey HSD post-hoc test for pairwise comparisons. A p-value 
of ≤ 0.05 was considered to be significant. In all graphs and 
tables, the mean values and standard deviation (SD) are shown. 
 
Electrospray mass spectrometry (ESI-MS) 
Samples were prepared by mixing 100M ubiquitin, (Ub, 
Sigma, U6253) with an excess of gold compound (300M)  (3:1, 
metal : protein molar ratio) in 20 mM (NH4)2CO3 buffer (pH 7.4) 
and incubated for 24 h at 37 °C. Prior to analysis samples were 
extensively ultrafiltered using a Centricon YM-3 filter (Amicon 
Bioseparations, Millipore Corporation) in order to remove the 
unbound complex. ESI-MS data were acquired on a Q-Tof 
Ultima mass spectrometer (Waters) fitted with a standard Z-
spray ion source and operated in the positive ionization mode. 
Experimental parameters were set as follows: capillary voltage 
3.5 kV, source temperature 80 °C, desolvation temperature 120 
°C, sample cone voltage 100 V, desolvation gas flow 400 L h−1, 
acquisition window 300–2000 m/z in 1 s. The samples were 
diluted 1 : 20 in water and 5 L was introduced into the mass 
spectrometer by infusion at a flow rate of 20 L min−1 with a 
solution of CH3CN/H2O/ HCOOH 50 : 49.8 : 0.2 (v : v : v). External 
calibration was carried out with a solution of phosphoric acid at 
0.01%. Data were processed using the MassLynx 4.1 software. 
Results 
Viability and TC50  
Complexes 1-3 (Figure 1) were tested for their possible toxicity 
in healthy rat kidney and liver PCTS 6,7. Kidney and liver slices 
were incubated with various concentrations of each gold 
complex and the viability of the tissues was determined 
measuring the ATP content after 24 h (Figure 2). Lansoprazole, 
cisplatin and auranofin were also tested for comparison. All the 
evaluated compounds, including cisplatin and auranofin, 
displayed a concentration dependent toxicity profile, with the 
dinuclear complex 3 and auranofin 46 as the most toxic, with a 
TC50 below 10 µM (Table 2). The ligand lansoprazole was 
poorly toxic in both organs. The neutral complex 2 is the least 
toxic of the three complexes, with TC50 values ca. 25 M in both 
liver and kidney, and the lowest observed anticancer effects in 
vitro. Of note, no significant differences were found for the 
toxicity of complexes 1 and 2 in kidney slices, despite 
differences in their antiproliferative effects in cancer cells, while 
1 was more toxic in liver slices (TC50 = 9±3 M). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Viability of rat PCKS and PCLS expressed as amount of ATP per mg protein relative to the controls (untreated slices) after treatment with complexes 
1-3, lansoprazole, cisplatin and auranofin for 24 h. The error bars show the standard deviation of three to six independent experiments. 
 
 Moreover, the mononuclear Au(I) complex 1 was two-fold less 
toxic than its dinuclear analogue 3 in both organs. 
Gene Forward (5’-3’) Reverse (5’-3’) 
ALDOA ACGAGGTTCTGGTGACCCTA CCGGAGCTACAATTCGGTGA 
ENO2 GTACCACACACTCAAGGGGG TCGTATTTGCCATCGCGGTA 
SLC2A1 TCAAACATGGAACCACCGCT AGAAACCCATAAGCACGGCA 
GCLM TCAAGCTCACAACTCAGGGG CGCCAGGGAGGTACTCAAAC 
HMOX-1 CACGCATATACCCGCTACCT AAGGCGGTCTTAGCCTCTTC 
p53 CCCCTGAAGACTGGATAAC AACTCTGCAACATCCTGGGG 
BAX ACAGGGGCCTTTTTGTTACAG GGGGAGTCCGTGTCCACGTCA 
SULF2 CGTGTGTGTTTAGAGGCGAGC AGCCTCTTTCCGCTTTTTGGT 
GAPDH CGCTGGTGCTGAGTATGTCG CTGTGGTCATGAGCCCTTCC 
 
 
The obtained ex vivo results were further related to the 
cytotoxicity observed towards the previously tested cisplatin-
sensitive and cisplatin-resistant cancer cells26 (Table 2). At 
variance with cisplatin, the gold compounds, including 
auranofin, showed a similar toxicity in these two cell lines, 
suggesting activity via different mechanisms of action 26. The 
safety margin for toxicity was calculated as the ratio TC50 
PCKS/EC50, where the TC50 is the concentration reducing the 
ATP content by 50% and the EC50 the concentration reducing the 
number of viable A2780R cancer cells for complex 1, 2 and 3 
and lansoprazole to 50%. In the case of complex 2 and 3 the 
safety margin for toxicity is poor, with values between 1.9 and 
8.9. Similarly, auranofin presents a low TC50 PCKS/EC50 ratio 
with values between 2 and 2.7. Instead, the TC50 PCKS/EC50 
cells ratio of complex 1 is ca. 27 for kidney, and ca. 13 for liver 
slices, indicating selective cytotoxicity towards both types of 
cancer cells compared to healthy tissue. 
 
Metal content analysis  
In order to assess the intracellular accumulation of the Au 
complexes and to evaluate the relationship between toxicity and 
cellular metal content, we determined the Au content in the 
PCKS and PCLS by ICP-MS. Additionally, the concentration of 
Pt was assessed in the slices exposed to cisplatin. 
 
Table 2. Toxicity of Au(I) complexes in PCKS and PCLS (TC50 values 
after 24 h incubation) and their comparison with the EC50 of the 
antiproliferative effects in cancer cell lines (72 h incubation). 
Compound EC50
a (µM) TC50
a (µM) TC50/EC50
b 
A2780 A2780R kidney liver kidney liver 
1 1.1±0.3 0.7±0.1 19±9 9±3 27.1 12.9 
2 16.2±1.1 13.2±4 .6 25±6 25±3 1.9 1.9 
3 1.5±0.3 0.9±0.4 8±5 4±1 8.9 4.4 
Lansoprazole 45.6±2.6 59.0±15.2 >75 >75 NR d NR d 
Cisplatin 2.4±0.6 35.0±7.0* 17±2 24±1 0.5 0.7 
Auranofin 1.25±0.5c 1.5± 0.3c 3±1 4±1 2.0 2.7 
a The reported values are the mean ± SD of three to six independent experiments. ND: Not 
determined  
b. EC50 of A2780R  
c Values taken from ref. 46 
d. NR: Not relevant 
 
PCKS and PCLS were incubated with the compounds for 24 h 
under the same conditions as for the viability experiments. 
Concentrations of cisplatin and Au complexes below their TC50 
were assessed in order to observe toxicity but guaranteeing 
having enough viable cells to have effective tissue accumulation. 
The metal content (Au or Pt) in the slices was evaluated using 
ICP-MS. As shown in Figure 3, metal uptake increases 
significantly as a function of the concentration. In the case of 
cisplatin, there is a higher accumulation of Pt in the kidney tissue 
compared with the liver, which is in line with the results obtained 
in previous studies 15.  
Conversely, for all the Au(I) complexes, the Au content is 
higher in liver than in kidney. Interestingly, both in liver and 
kidney slices, the dinuclear complex 3 caused a higher 
accumulation of Au than its mononuclear analogue (complex 1). 
However, the accumulation of Au for complex 3 at 5 µM is 5-8-
fold higher than for complex 1 at 5 µM, which is much higher 
than the two-fold difference in Au content between the two 
complexes.  
In the case of kidney slices the average metal content was 14.3 
and 111.78 ng of Au per mg of tissue when treated with complex 
1 and 3 (5 µM), respectively. Accordingly, in the liver slices the 
average metal content at 5 µM of complex 1 and 3 was 39.2 and 
193.9 ng of Au per mg of tissue, respectively, although at this 
concentration the viability of PCLS and PCKS was not different 
(Figure 2). Thus, the higher metal content in the liver slices might 
account for the lower TC50 in liver compared to kidney slices for 
both compounds.  
Concerning the neutral Au(I) complex 2, despite its lower 
toxicity (Table 2), Au uptake is comparable to complex 1 in both 
organs. Finally, the Pt accumulation in both tissues treated with 
cisplatin (Figure 3D) is always lower than the Au accumulation 
observed in the case of complexes 1-3. 
 
Figure 3. Total metal content (Au or Pt) determined by ICP-MS in kidney and 
liver slices exposed to complexes 1-3 and cisplatin after 24 h incubation. The 
error bars show the standard deviation of two independent experiments. 
 
Histomorphology 
In order to explore the localization of the damage in the different 
histology structures of the kidney induced by the Au compounds 
compared to cisplatin, morphological analysis of the PCKS was 
performed. The characteristic toxic effects on kidney slices of 
complexes 1-3, cisplatin and auranofin were evaluated at a 
concentration close to the calculated TC50 for each compound 
(25 µM for complexes 1, 2 and cisplatin; 10 µM for complex 3 
and 5 µM for auranofin). Lansoprazole was not included in this 
evaluation because of the low toxicity observed during the 
viability experiments. Periodic acid-Schiff staining (PAS) was 
used to evaluate the integrity of the kidney slices and particularly 
to visualize the basement membranes and epithelial brush border 
in the proximal tubule cells, as reported in the experimental 
section. After 24 h incubation, the untreated kidney slices show 
minor morphological changes, such as occasional pyknosis and 
swelling of some of the tubular cells (Figure 4A). Pronounced 
toxic effects were observed upon treatment with complexes 1, 2, 
3 and auranofin which induced dilatation of Bowman’s space in 
the glomerulus and necrosis of the distal tubule cells, as well as 
  
 
discontinuation of the brush border in some of the proximal 
tubule cells (Figure 4B, 4C, 4D and 4F). Similar toxic effects 
were observed in PCKS exposed to a Au(I) N-heterocyclic 
carbene complex, which induced similar features in the 
Bowman’s space in the glomerulus and in the distal and proximal 
tubule cells21. In contrast, exposure of slices to cisplatin (Figure 
4E) showed injury to the proximal tubular cells with loss of 
nuclei and more distinct damage of the brush border; 
additionally, damage of the distal tubule is evident as previously 
reported in the literature16,21. 
 
Stress markers expression  
To get insight in the specific type of stress that the Au complexes 
induced in this study, we studied the mRNA expression of 
selected specific genes that code for proteins that belong to 
pathways that are activated under hypoxia (Hif1a) 47, oxidative 
stress (Nrf2) 48 and DNA damage (p53) 49.  
Based on the work of Limonciel, et al. 50, we chose two or three 
genes related with the mentioned pathways that displayed 
significant up or down regulation after treating human and rat 
hepatocytes, and RPTEC/TERT1 cells (human renal proximal 
tubule cell line transfected with human telomerase) with several 
known toxicants 50. Each of the selected bio-markers was 
expressed by kidney and liver cells. For these experiments liver 
and kidney slices were treated with the compounds at 
concentrations close to the calculated TC50 values (1 and 10 µM 
for complex 1 and 3, 5 and 25 µM for complex 2, 50 and 75 µM 
for lansoprazole) during 24 h.  
From the Hif1α (hypoxia-inducible factor 1 α) pathway, we 
selected to evaluate the expression levels of ALDOA that codes 
for fructose-bisphosphate aldolase A enzyme, ENO2 that codes 
for enolase 2, and SLC2A1 that codes for the glucose transporter 
protein type 1 (GLUT1). All these genes promote survival of 
cells in hypoxic conditions by inducing glycolysis 47. In the case 
of PCKS no significant up or down regulation of any of the 
selected genes was observed (Figure 5), indicating that the 
compounds do not promote a hypoxic environment as a toxicity 
mechanism. In the case of PCLS, the responses were more 
diverse, where exposure of PCLS to complex 1 seemed to induce 
an upregulation of SLC2A1 gene at the highest concentration 
only. 
Moreover, treatment with complex 3 at 10 µM induced 
upregulation of ca. 3-fold of ENO2 compared with the untreated 
samples. These results suggest some activation of the hypoxia 
pathway in the liver slices. Lansoprazole did not induce any 
change in the expression of the tested genes. Further experiments 
are necessary to fully understand if activation of the hypoxia 
pathway is the main cause of toxicity, specifically in the case of 
liver tissue, using different bio-markers, such as Hif1α and 
FABP3 (fatty acid binding protein 3) 47,51.  
The selected genes from the Nrf2 pathway include GCLM 
and HMOX-1. GCLM codes for glutamate-cysteine ligase 
modifier subunit of glutamate-cysteine ligase and is the first and 
rate-limiting step enzyme of the glutathione biosynthetic 
pathway 52. HMOX-1 codes for heme oxygenase 1, which is an 
essential enzyme in heme catabolism and plays an important role 
as antioxidant under oxidative stress conditions 53. Both genes 
are overexpressed under oxidative stress conditions in kidney 
and liver tissue to detoxify the excessive production of free 
radicals 54–56. GLCM expression was significantly upregulated 
by the higher concentration of complex 3 in kidney slices, 
whereas in liver slices the effect was not evident. HMOX-1 
expression was also significantly upregulated by the higher 
concentration of complex 3 in kidney and liver slices. A trend 
towards upregulation of HMOX-1 was observed after treatment 
of PCKS and PCLS with complexes 1 and 2; although the 
differences are not significant in all cases, an analysis of the 
individual experiments revealed a trend towards upregulation of 
both genes (Figure 6). Furthermore, lansoprazole did not induce 
any change in the expression of the tested genes. Additional 
experiments evaluating the glutathione and thioredoxin 
intracellular redox balance could lead to confirmation of our 
findings. 
The p53 pathway was also explored by determining the 
expression levels of protein p53. Protein p53 stimulates the 
expression of a set of arrest-upon-cellular-stress signals induced 
by DNA damage, downstream target genes that are involved in 
induction of apoptosis, facilitation of DNA repair or activation 
of cell cycle oncogene activation and hypoxia 57–60. BAX codes 
for the Bcl-2- enzyme sulfatase 2, which is upregulated upon 
activation of p53 due to DNA damage, thereby affecting the cell 
cycle 61. Neither p53, BAX or SULF-2 showed major regulation 
changes upon treatment of kidney and liver slices by any of the 
tested compounds (Figure 7). These findings are in line with the 
lack of caspase 3 and 7 activation observed in PCKS (data not 
shown), indicating that apoptosis via DNA damage is not the 
mechanism of gold compounds’ induced cell death in tissue 
slices. Conversely, cisplatin covalently binds DNA nucleobases 
leading to apoptosis as the main mechanism of toxicity, with 
marked upregulation of p53 and BAX 62–64.  
 
Reactivity with model protein Ubiquitin 
In order to shed light on the reactivity of the Au complexes we 
investigated their interactions with ubiquitin (Ub), used as a 
model protein, by electrospray ionization mass spectrometry 
(ESI-MS) following established protocols 46,65,66. Ub is a small 
tightly folded protein of 76 amino acids which has several 
potential binding sites for metal centers, including a Met residue 
with high affinity for Au binding 66. Thus, three molar 
equivalents of complexes 1 and 2 were added to an aqueous 
solution of Ub buffered at pH 7.4 (see Experimental for details). 
Figure S1 in the supplementary material shows the mass spectra 
of the Ub–1 and Ub-2 samples recorded after 24 h incubation. In 
the spectrum, Ub was identified as one of the main peaks at 
952.65 m/z (charge state +9, ca. 8565 Da), and gold-containing 
 
 
species were observed at 974.45 m/z (charge state +9, ca. 197 
Da) corresponding to an Ub–Au adduct in which the original 
lansoprazole ligand is absent. The observed reactivity is similar 
to the one described for the reference compound auranofin 67 and 
similar Au(I) complexes 46. 
 
 
 
 
Figure 4. Morphology of rat kidney slices. A: 24 h control incubation; B: complex 1 (25 µM); C: complex 2 (25 µM); D: complex 3 (10 µM); E: 
cisplatin (25 µM) and F: auranofin (5 µM). PT: proximal tubule, DT: distal tubule, G: glomerulus. Scale bar indicates 50 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 5. Gene expression of ALDOA (A), ENO2 (B) and SLC2A1 (C) in kidney (black bars) and liver slices (grey bars) exposed to complexes 1, 
2, 3 and lansoprazole for 24 h, in comparison to untreated slices set as 1. The error bars show the standard deviation of three independent experiments. 
Statistical significance (p < 0.05) is shown as *.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Gene expression of GCLM (A) and HMOX-1 (B) in kidney and liver slices exposed to complexes 1, 2, 3 and lansoprazole for 24 h, in 
comparison to untreated slices set as 1. The error bars show the standard deviation of three independent experiments. Statistical significance (p < 
0.05) is shown as *. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 7. Gene expression of p53 (A), BAX (B) and SULF-2 (C) in kidney and liver slices exposed to complexes 1, 2, 3 and lansoprazole for 24 h, 
in comparison to untreated slices set as 1. The error bars show the standard deviation of three independent experiments. Statistical significance (p < 
0.05) is shown as *. 
 
Discussion and conclusions 
The potential therapeutic application of lansoprazole Au(I) 
complexes with antiproliferative effects 26 prompted us to study 
their toxicity in healthy tissue using kidney and liver slices, 
aiming to predict the possible side effects when the complexes 
are administered in vivo. Thus, the toxicity was evaluated by 
measuring the ATP content as well as by histomorphology and 
metal content analysis by ICP-MS, in PCTS. Additionally, 
mRNA expression of specific stress markers was assessed in 
tissue slices, including expression of genes coding for proteins 
that play important roles in pathways of oxidative stress, 
apoptosis and hypoxia. The obtained ATP results showed a 
different toxicity profile for the tested compounds. The neutral 
complex 2 shows the lowest toxicity in both liver and kidney 
slices, also lower than cisplatin, followed by the cationic 
complex 1, whereas the dinuclear and cationic complex 3 is the 
most toxic in the liver and kidney slices. Notably, both 
complexes 1 and 3 bear triphenylphosphine ligands, known to be 
intrinsically toxic, 34 while the PTA (1,3,5-triaza-7-
phosphaadamantane) ligand of complex 2 is non-toxic. As 
expected, in kidney and liver slices complex 1 (with one 
phosphine ligand and one Au ion) is less toxic than the dinuclear 
diphosphane complex 3. However, as the amount of Au taken up 
was reasonably well in line with the toxicity, based on the TC50 
via ATP determination, the higher Au uptake of 3, combined to 
the phosphine activity, may be mainly responsible for the higher 
toxicity.  
Considering that the selectivity of a compound for cancer 
cells compared to healthy organs is the most relevant parameter 
when selecting it for further preclinical trials, the ratio of the 
TC50 in slices to the EC50 in the cisplatin-resistant cancer cells 
was calculated for each gold compound. Using this parameter, 
 
 
complex 1 presents the best ratio of toxicity in healthy tissue to 
anticancer efficacy when compared to the other tested 
complexes. This ratio is also much higher for complex 1 than for 
cisplatin, which may indicate that this compound can lead to a 
promising drug candidate for further development. However, it 
should be stressed that these ratios do not represent the absolute 
values of selectivity, because the cancer cell lines model and the 
tissue slices are different. Nevertheless, the calculated ratios can 
be used to compare the different compounds with standard 
anticancer drugs like cisplatin.  
Furthermore, the histomorphology evaluation shows 
similarities for all three Au(I) complexes with respect to the 
specific kidney cell types that suffer the most extensive damage, 
as they seem to be preferentially toxic towards the distal tubular 
cells. This result is in contrast to cisplatin, which is known to 
show toxicity mainly in the proximal tubular cells as described 
in previous reports 16,21,22.  
ICP-MS data on PCTS treated with the Au(I) complexes 
show that in all cases the Au content is higher in the liver PCTS 
than in the kidney PCTS, at variance with the Pt content for 
cisplatin treated slices. Nevertheless, marked differences in the 
uptake and extent of cellular damage of the Au complexes were 
also observed, particularly considering the efficient Au 
accumulation for the dinuclear cationic derivative 3. It is also 
worth mentioning that, despite the lower toxicity of complex 2 
compared to cisplatin in PCTS, the Au content in the slices was 
higher than the Pt content as shown by ICP-MS. The observed 
toxic effects may also depend on the accumulation of the 
compounds in specific cell types. Overall, these results 
corroborate the idea of different mechanisms of tissue 
accumulation and sub-cellular localization of the tested 
metallodrugs 68. The fact that the Au(I) complex 2 is neutral, and 
the other two, 1 and 3 positively charged, may well differentiate 
its uptake and cellular localization.  
In terms of the possible reactivity, it should be noted that 
previous studies on Au(I) complexes with N-donor and 
phosphine ligands have evidenced that these compounds are 
prone to ligand exchange processes upon reaction with 
intracellular proteins/enzymes (e.g. via binding to Cys and Met 
residues)46,66,69. According to these results, upon thiol and 
thioether binding, the Au(I) complexes release their ligands and 
the ‘free’ gold ions remain bound to the amino acid side chains. 
In addition, further reduction of Au(I) to Au(0) upon protein 
binding cannot be excluded. In this study, the ESI-MS results 
confirm the lansoprazole and phosphine ligands’ loss upon 
binding to the model protein ubiquitin of compounds 1 and 2. 
Interestingly, based on the gene expression data, of all the 
stress pathways evaluated, the clearest impact of the compounds’ 
administration was on the Nrf2 pathway, indicating oxidative 
stress as a possible mechanism of toxicity. Instead, no indication 
of apoptosis induction via DNA binding and upregulation of p53 
and BAX was observed, at variance with cisplatin.  This result is 
in line with previously reported data, according to which Au(I) 
complexes cause the inhibition of the seleno-enzyme thioredoxin 
reductase (TrxR) involved in the maintenance of the intracellular 
redox balance 70,71. In future studies, it might be relevant to 
include specific markers for distinct cell types in the kidney and 
the liver to get more information about the cell-specific toxicity 
of the compounds evaluated in this study. 
The obtained results open new perspectives towards the 
understanding of the selectivity and mechanism of toxicity of the 
lansoprazole-based Au(I) complexes and prompt us to pursue the 
design of new families of anticancer bifunctional gold 
compounds, with reduced toxicity in healthy tissues. 
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